Furthermore, analysis of the tumor specimens in Cohort II using the antibody that was used in the breast cancer study [16] yielded concordant results regarding the prognostic impact of tumor-specific RBM3 expression (data not shown). This evidence concerns the gene RBM3 and neoplasm.